Pancreatic mucinous cystadenoma with serum CA 19-9 over 1,000,000 U/mL: a case report and review of the literature

被引：2

作者：

Costa, Wilson L., Jr. ^{[1
]}

Mantoan, Henrique ^{[1
]}

Brito, Rafael Horacio ^{[1
]}

Ribeiro, Heber S. C. ^{[1
]}

Diniz, Alessandro L. ^{[1
]}

Godoy, Andre Luis ^{[1
]}

Farias, Igor Correia ^{[1
]}

Begnami, Maria Dirlei F. S. ^{[2
]}

Soares, Fernando Augusto ^{[2
]}

Coimbra, Felipe J. F. ^{[1
]}

机构：

[1] AC Camargo Canc Ctr, Dept Abdominal Surg, BR-01501900 Sao Paulo, Brazil

[2] AC Camargo Canc Ctr, Dept Surg Pathol, BR-01501900 Sao Paulo, Brazil

来源：

WORLD JOURNAL OF SURGICAL ONCOLOGY | 2015年 / 13卷

关键词：

Pancreatic cystic lesions; Biomarkers; CA19-9; CARBOHYDRATE ANTIGEN 19-9; CYSTIC NEOPLASMS; CA19-9; LEVELS; ADENOCARCINOMA; DIAGNOSIS; EXPERIENCE; SURVIVAL; LESIONS; BENIGN;

D O I：

10.1186/s12957-015-0476-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The diagnosis of pancreatic cystic neoplasms has become more accurate recently. In some cases, however, doubt remains regarding the lesion's malignant potential. CA 19-9 has long been identified as a reliable biomarker in differentiating pancreatic benign and malignant lesions, especially in non-jaundiced patients. Case report and discussion: We report a case of a young female who presented with a mucinous lesion in the tail of the pancreas and a serum CA 19-9 over 1,000,000 U/mL. She was taken to surgery and had a distal pancreatectomy and splenectomy. Pathology reports showed only a mucinous cystadenoma. After 1 year of follow-up, her serum CA 19-9 was normal. Following that, the work-up in these lesions, the role of the biomarker in pancreatic adenocarcinoma and in the differentiation between benign and malignant lesions is discussed.

引用

页数：5

共 22 条

[1] A selective approach to the resection of cystic lesions of the pancreas - Results from 539 consecutive patients [J].

Allen, Peter J. ;

D'Angelica, Michael ;

Gonen, Mithat ;

Jaques, David P. ;

Coit, Daniel G. ;

Jarnagin, William R. ;

DeMatteo, Ronald ;

Fong, Yuman ;

Blumgart, Leslie H. ;

Brennan, Murray F. .

ANNALS OF SURGERY, 2006, 244 (04) :572-582

[2] CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice [J].

Duraker, Nuevit ;

Hot, Semih ;

Polat, Yuecel ;

Hoebek, Anil ;

Gencler, Nur ;

Urhan, Nuray .

JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (02) :142-147

[3] Cystic lesions and intraductal neoplasms of the pancreas [J].

Fasanella, Kenneth E. ;

McGrath, Kevin .

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2009, 23 (01) :35-48

[4] Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].

Ferrone, Cristina R. ;

Finkelstein, Dianne M. ;

Thayer, Sarah P. ;

Muzikansky, Alona ;

Fernandez-del Castillo, Carlos ;

Warshaw, Andrew L. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902

[5] Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas [J].

Fritz, S. ;

Hackert, T. ;

Hinz, U. ;

Hartwig, W. ;

Buechler, M. W. ;

Werner, J. .

BRITISH JOURNAL OF SURGERY, 2011, 98 (01) :104-110

[6] Small (Sendai Negative) Branch-Duct IPMNs Not Harmless [J].

Fritz, Stefan ;

Klauss, Miriam ;

Bergmann, Frank ;

Hackert, Thilo ;

Hartwig, Werner ;

Strobel, Oliver ;

Bundy, Bogata D. ;

Buechler, Markus W. ;

Werner, Jens .

ANNALS OF SURGERY, 2012, 256 (02) :313-320

[7]

God DV, 2013, CANCER, V119, P522

[8]

Jesipowicz J, 2000, WSPOLCZESNA ONKOL, V4, P76

[9]

Joergensen MT, 2010, ANTICANCER RES, V30, P587

[10] Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience [J].

Jones, Natalie B. ;

Hatzaras, Ioannis ;

George, Nathaniel ;

Muscarella, Peter ;

Ellison, E. Christopher ;

Melvin, W. Scott ;

Bloomston, Mark .

HPB, 2009, 11 (08) :664-670

← 1 2 3 →